Wall Street Researcher
BREAKOUT ALERT
PetVivo Holdings Inc
PETV NASDAQ
Target Price $7.00 By Think Equity Research Report
CEO INTERVIEW MARK MIDDLETON INTERVIEW
Earnings And Business Update Call Transcript
Insider Buying !
| Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC –Cell : 516 – 455-7662 – EMAIL – gzplumtree@gmail.com |
PetVivo Holdings, Inc. Announces Formation of Nonprofit PetVivo Cares To Advance The Health & Well-Being of Companion Animals
Recently these shares spiked above $2.60 before settling back to current levels, all on news of a major distribution agreement with a top Veterinary Supply and Services Company. ( See Press Release Below )
__________________________________________
These shares are ready to BREAKOUT above its 200 day moving average of $2.37 . With a yearly high of $8.80 we expect PETV shares to continue to advance on upcoming news on developing products and patents .The company has 19 patents with a pipeline of 17 products.
We urge all serious investors to place these shares immediately on their BUY LIST.
PetVivo Holdings, Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently-regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products containing propriety thermoplastic protein based biomaterials that mimic the bodys tissue. a portfolio of 19 patents and 8 pending patent applications protects the companys biomaterials, products, production process and methods of use.
WEBSITE MANAGEMENT RESEARCH REPORT CEO INTERVIEW
PetVivo Holdings, Inc. Announces Formation of Nonprofit PetVivo Cares To Advance The Health & Well-Being of Companion Animals
MINNEAPOLIS, July 19, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for pets, is pleased to announce the launch of a philanthropic endeavor called PetVivo Cares, a registered 501(c)(3) organization.
PetVivo Cares is partnering with the animal healthcare community to advance the health and well-being of animals experiencing discomfort from lameness or other joint related afflictions, such as osteoarthritis. “We take our goals seriously,” said Scott Herold, Executive Director of PetVivo Cares. “Our mission is to provide animal-based nonprofits & companion/therapy animal organizations, with no-cost or reduced-cost Spryng ™ with OsteoCushion™ Technology. PetVivo Cares is dedicated to providing the best quality of life for your pets so that you can focus on loving and enjoying your companion animal.”
PetVivo and PetVivo Cares have a genuine passion for animals. To demonstrate this passion, PetVivo has set a goal to donate 500 no-cost Spryng injections to animal organizations. Spryng, an injectable veterinary medical device administered by licensed veterinarians, will be provided on a financial or critical needs basis. With the support of private donations, PetVivo Cares can grow the success stories exponentially, expanding the PetVivo’s reach to treat even more dogs, cats, horses and other animals suffering from lameness and other joint related afflictions.
“We are very excited to be able to give back to the animal care community, via its numerous and dedicated organizations,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We’ve gotten to know so many wonderful animals as well as people, and we are excited to discover how we can further help animals experiencing joint discomfort. Nothing is better than seeing an animal recover and spring back into action after treatment.”
Leading PetVivo Cares as Executive Director is Scott Herold, multi-award-winning philanthropist, youth advocate, and nonprofit record label executive. Herold is a seasoned veteran of the nonprofit world and his work with Rock the Cause Records and High School for Recording Arts is well respected in philanthropic circles. “Much of my work has been focused on arts and underserved youth. I am looking forward to discovering new ways of serving our community through its beloved animal friends,” said Mr. Herold.
Designed by Stickerbook Collective, PetVivo Cares is launching a dynamic new website in celebration of its pet wellness strides. The PetVivo Cares website will feature the personal triumphs of each pet receiving Spryng with individual blog posts to track their journeys to joint recovery. In addition to TikTok and Instagram reels, PetVivo Cares will be featuring blog posts on Pinterest, so you can meet the charming personalities of our clients. To find out more about our revolutionary product or to see if your organization qualifies for a PetVivo Cares Spryng grant visit petvivocares.org or call 1-888-478-8273. You can also follow us @petvivocares on all social platforms.
Spryng is only sold in the United States and its territories. For more information about Spryng also visit the technology page on petvivocares.org .
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG ™ with OsteoCushion ™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/
About PetVivo Cares, Inc.
PetVivo Cares is a nonprofit community-focused organization dedicated to advancing the health and well-being of companion animals. We partner with the animal health community to provide reduced-cost or no-cost SPRYNG ™ with Osteo-Cushion Technology, a product developed by PetVivo, Inc. (“PetVivo”). SPRYNG ™ is an effective tool to aid in the management of osteoarthritis, lameness, and rehabilitation of companion animals.
PetVivo Cares wants to enhance the lives of companion animals by helping to make SPRYNG ™ available to animals who may not have the opportunity to receive it. Discover PetVivo Cares at petvivocares.org or follow our socials @petvivocare
PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION SERVICES AGREEMENT WITH MWI ANIMAL HEALTH
MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine athletes and companion animals, announced today it has entered into a definitive exclusive distribution services agreement with MWI Animal Health, a leading distributor of animal health products and services and a subsidiary of AmerisourceBergen.
MWI will inventory, market, and promote PetVivo’s veterinary medical device, Spryng ™ with OsteoCushion ™ Technology, throughout the United States. Through its network of distribution centers in key markets nationwide, MWI can support efficient deliveries to communities nationwide.
“We are pleased with the commitment MWI has made to PetVivo in the roll out of this new relationship that includes the distribution of our lead product, Spryng. We view MWI as a strategic partner that will allow PetVivo significant exposure to and penetration in the US animal health market. This new relationship will benefit the industry, the veterinarian who provides the medical care, their patients and the pet owner alike,” stated John Lai, Chief Executive Officer for PetVivo.
PetVivo’s innovative product, Spryng with OsteoCushion Technology, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from natural biocompatible components. OsteoCushion Technology provides both reinforcing natural joint support to augment and reinforce missing and/or damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
“We continue to see tremendous innovation across the animal health industry, including the emergence of novel therapies and devices. We work closely with companies leading these efforts to ensure veterinarians nationwide have access to the latest products and services that have the potential to help pets live longer and healthier lives,” said Steve Shell, president of MWI Animal Health. “We are thrilled to work with PetVivo to provide veterinarians with timely and reliable access to the company’s new medical device.”
PetVivo Holdings Inc. (PETV:NASDAQ) is a small, and on the outside, unassuming biomedical device company based in Minnesota. Yet, its CEO John Lai is not the typical prototype executive you would expect to be running a biomedical company. John had a successful career on Wall Street, identifying companies with good products or services that held massive opportunities for a better-than-average return on investment. His unique skillset led John to start his own firm, where he was introduced to the PetVivo story.
After his due diligence, Lai recognized that PetVivo’s all-natural products could provide comfort to millions of pets suffering from osteoarthritis. It had the science, patent protection, and a huge addressable market. It all looked well and good, so John decided to join PetVivo and take the company.
Two Setbacks on the Path to Success
However, this did not come without its setbacks. After a series of unfortunate circumstances—including a four-year audit involving the medical device company that PetVivo merged with to become a publicly-traded company—the stock price suffered, leading to a series of reverse splits.
PetVivo has been on a rough road, and the company has faced some significant challenges. Under Lai’s leadership and his and his team’s passion, I would suggest that the company has positioned itself to excel in the months and years to come.
Still, Lai and PetVivo did not give in and leave with their tails between their legs. Instead, they took an unexpected turn in the right direction. John used his background in the capital markets and did not allow the company to do any death spiral financings. John, and a few believers in his abilities and PetVivo’s value proposition, stepped up and made an awe-inspiring move to support the company and get through the tough times without blowing up the cap table. In the end, PetVivo completed the lengthy process of a four-year audit without any material changes occurring.
PetVivo’s executive team focused on building up their manufacturing capabilities to bring them in line with the projected demand. It also helps that PetVivo is not reliant upon foreign entities for its products. There are no supply chain issues to be concerned over. All its manufacturing needs can be met and expanded with a minimal cap-ex spend at its facility in Minneapolis, Minnesota. The PetVivo ISO certified clean room facility currently has the capacity for 500k doses annually.
Yet, on its road to success, PetVivo had to face another hurdle. Covid-19 struck in 2020, causing another setback that impacted the progress of achieving scale and significant sales growth. Due to quarantine, PetVivo was limited in its ability to meet with veterinarians to educate them on these new Osteoarthritis solutions.
Why PetVivo?
While they had to overcome many difficulties, PetVivo has a plethora of benefits that aid in its upward mobility. For one, PetVivo’s “Spryng with OsteoCushion” product has been given to hundreds of horses and dogs through a single injection to treat joint pain due to the loss of cartilage. What makes the product extremely compelling is that it is an all-natural solution. According to their website, “Spryng is a comprised of two naturally derived proteins (collagen and elastin) and one carbohydrate.”
Osteoarthritis affects approximately 14 million adult dogs and 1 million horses. It causes pain and inflammation from degenerated cartilage of stressed joints. Eventually, lameness worsens from the ongoing loss of cartilage and the inflammation present in the joint. While there are medications to manage this, the current solutions treat the symptoms rather than manage the cause.
The Optimal Osteoarthritis (OA) Solution: Spryng With OsteoCushion Technology
Spryng provides a biocompatible lubricious cushion, which reinforces the cartilage barrier between the bones to protect the remaining cartilage and bone and improve joint function. It does this by using similar components/functions found in natural cartilage (i.e., collagen, elastin, and heparin). Spryng particles are injected into the synovial space with standard intra-articular injection technique; multiple joints can be injected simultaneously.
Case studies indicate long-lasting (e.g. ~12 months or longer) improvement in lameness. Spryng also avoids NSAIDs side effects by minimizing their use, making it an effective and economical solution for managing OA.
The anecdotal evidence that Spryng has received has been overwhelmingly positive compared to the other potential solutions on the market today. However, to effectively get the veterinarians to prescribe Spryng, PetVivo needs more than anecdotal evidence; they need to conduct animal studies with documented results. Covid-19 played a role in delaying the data to be provided from the animal studies as well as making it more difficult to speak with veterinarians about this solution.
These setbacks are discouraging for investors that have been involved since the beginning. Still, I don’t suggest we fret yet. The good news is that with Covid-19 no longer being a severe enough issue to shut down the economy, businesses are getting back to a more normalized work environment, and Lai refused to spend the downtime sitting around.
During the halt, Lai managed to assemble an all-star team of executives to help execute his vision for the company. The level of talent that has decided to join the company would not be jumping on board unless there was something they felt has the real promise of success in the portfolio.
Potential Catalysts on the Horizon
Statistically significant results should be presented within the next two quarters with the independent animal studies back on track. Those results will help validate PetVivo’s Spryng therapy, priced at a much lower cost to the consumer than today’s alternative treatments. There is potential for new distribution partnerships and pet insurance coverage as well. A much larger pet care company could also be interested in acquiring PetVivo at the current depressed price levels.
The Spryng treatment, because of its natural ingredients, could open up a whole new way of potentially preventing the onset of Osteoarthritis by performing the injection ahead of complete deterioration of the cartilage, especially for horses and large-breed dogs.
PetVivo has been on a rough road, and the company has faced some significant challenges. Under Lai’s leadership and his and his team’s passion, I would suggest that the company has positioned itself to excel in the months and years to come.
Technically, the stock price seems to have found significant support in the $1.25 area. There will likely be resistance in the two dollars and $2.50 areas. The big area to take out would be the $3.00 range. If the share price were able to close above that level, I could easily see a run to $5.00 on any meaningful fundamental news. If the share price were to close below $1.25, it could see a flush below $1.00.
However, without any significant fundamental news to justify that drop, I would view that as an opportunity to get aggressive in building my position. With just around 10 million shares outstanding and around 6 million in the float, insider support/participation, and no debt. I believe the risk-reward is favorable at these levels.
For more information, click the link to watch my full interview with PetVivo CEO John Lai.
Corp Interview
New to The Street TV welcomes Mr. Mark Middleton, National Sales Director at PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW), for his interview with TV Host Jane King. PetVivo Holdings, Inc. is a biomedical device company that focuses on manufacturing, commercialization, and licensing innovative medical devices and therapeutics for companion animals. As PETV’s National Sales Director , Mark talks about his history within the pet products industry, dealing with FDA manufacturing, product distributions, capital markets, and mergers/acquisitions. He sees himself as a perfect fit at PETV; he understands the veterinarians (DVMs) needs for best practices and product result outcomes for their clients’ animals. The injectable patented Spryng with OsteoCushion Technology treats osteoarthritis and joint afflictions while providing rehabilitation treatments for horses and dogs and continues to grow as a reliable DVM treatment. Being an entirely naturally derived product, Spryng is superior to competitors’ non-biological, synthetic products, and the Spryng treatment lasts longer. The PETV has a talent team who understands science, finance, sales/marketing, manufacturing, distribution, etc. With patience, persistence, and follow-through, Mark sees a strong future for PETV. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. – https://petvivo.com/ and Spryng with OsteoCushion Technology – https://www.sprynghealth.com/ .
About PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW):
PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies to treat companion animals in a capital and time-efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices that enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products to treat animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes, and use methods. The Company’s lead product Spryng with OsteoCushion Technology , a veterinarian-administered, intraarticular injection to treat lameness and other joint-related affliction, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians – https://petvivo.com/ & https://www.sprynghealth.com/ .
Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is not a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.. All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly